CYP2D6 genotype and debrisoquine metabolic ratio (MR) were analyzed in 133 Nicaraguan Mestizos (NMs) and 260 Cubans divided into Cuban Mestizos (CMs) and White Cubans (WCs). The frequencies of poor metabolizers (MRX12.6) were 6% in NMs, 3.9% in CMs and 5.3% in WCs. The frequencies of ultrarapid metabolizers (MRp0.1) were 0% in NMs, 2.3% in CMs and 5.3% in WCs. Mean (±s.d.) MR among extensive metabolizers (MRo12.6) was higher in NMs (1.5 ± 1.6; n ¼ 118) than in CMs (1.0 ± 1.3; n ¼ 124; Po0.001) and WCs (0.7 ± 1.0; n ¼ 124; Po0.001). MR correlated with the 'activity score' of CYP2D6 genotypes (Po0.05; r ¼ À0.55). Mean MR was higher among NMs than WCs and CMs for groups classified as 1 (Po0.05) or 2 (Po0.01) 'activity score'. In addition, mean (±s.d.) MR was higher among subjects carrying CYP2D6*17 than in CYP2D6 wt/wt (Po0.001). The CYP2D6*10 allele was higher in NMs (3.1%) than in CMs (0.8%; Po0.05) and WCs (0.4%; Po0.05). CYP2D6*17 allele was higher in CMs (10.2%) than WC (2.7%; Po0.005) and NMs (0%). Thus, the variability in CYP2D6 phenotypes found may be related to differences in allele frequency among groups (that is, CYP2D6*10 and *17 highest in NMs and CMs, respectively). However, the influence of environmental factors or alleles different than those studied here cannot be ruled out.
Introduction
Interethnic differences in cytochrome P450 polymorphism might be partially responsible for the variations in drug disposition between populations. Cytochrome P450 2D6 (CYP2D6) is of great importance for the metabolism of B25% of all clinically used drugs. Phenotyping with specific probe drugs, such as debrisoquine, sparteine or dextromethorphan, allows classifying individuals into two hydroxylation phenotypes: Poor (PMs) and extensive metabolizers (EMs), including a group of individuals with very rapid enzyme activity or the so called ultrarapid metabolizers (UMs). 1 The worldwide distribution of PMs varies markedly. In Europe, PMs are more common (5-10%) than in Asia (B1%), whereas in Africa PMs are reported to range from 0 to 19%. [2] [3] [4] In Latino populations, the frequency of PMs is also variable ranging from 3.2 to 10% (Table 1) . In Amerindian groups, PMs range from 0% in Mexican Tepehuano and in Panamá Cuna to 4.4% in Ngawbes living in Colombia and Panama (Table 1) . However, few studies have estimated the frequency of UMs in Latino or Amerindian populations, being the frequency in Spaniards of 5.2%.
The CYP2D6 is a highly polymorphic gene localized on chromosome 22q13.1. The CYP2D6 alleles are related to absent, decreased, normal and increased catalytic activity (http://www.cypalleles.ki.se/cyp2d6.htm). CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6 are the most important variants related to absent enzyme activity and CYP2D6*10 and CYP2D6*17 to reduced enzyme activity. The frequency of CYP2D6 alleles varies amongst ethnic groups. The most frequent non-functional alleles for Caucasians are in order CYP2D6*4, CYP2D6*5 and CYP2D6*3 (Table 1 ). CYP2D6*10 is more frequent in Asians, 18 and CYP2D6*17 in Black Africans. 19 Considering that Latinos have besides Caucasian, Amerindian and African ancestors, a large representation of non-functional but also of reduced function alleles is expected to be found. The frequency of individuals with duplicated CYP2D6 active alleles has been set around 5% in Spain, 20 0.69% in Asia 21 and 29% in Ethiopia. 3 However, there are few reports in Latino populations, and it is not clearly shown whether the multiplication is of active alleles (Table 1) .
CYP2D6 genotyping is widely used to evaluate enzyme activity, but a perfect match between genotype and phenotype has been only observed in individuals with zero active genes, whereas using the most common classification of 0, 1, 2 and 42 active genes. This correlation has been largely improved since Gaedigk et al. 22 proposed the 'activity score' concept, which has been probed using dextromethorphan as substrate test. Therefore, it first appears of scientific interest to analyze it using debrisoquine, which is one of the most accurate markers of CYP2D6 hydroxylation capacity. Second, considering that United States Food and Drug Association has already approved drugs with prescribing guidelines targeted toward specific ethnic groups, it is also of relevance to study groups that might be representative of Latin American populations, including the largest minority (15%) in United States of America. The studied populations in this study resemble the constitution of Latinos; three groups with an expected higher Caucasian (White Cubans; WC), African (Cuban Mestizos; CM) or Amerindian (Nicaraguan Mestizos; NM) ancestry component. Therefore, this study was aimed to determine whether there were differences in the frequency of CYP2D6 PMs and UMs, and the most common and relevant CYP2D6 alleles across the studied populations. The genotype-phenotype relationship 
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Materials and methods

Subjects and procedure
The Cuban population was divided into two groups: 'Whites' WCs that were those individuals with four Caucasian grandparents and 'Mestizos' CMs that represented the rest. The subjects were mostly Medical and Nursing school students and staff from the Faculty of Medicine 'Calixto García', Psychiatric Hospital of Havana (Cuba) and 'Universidad Nacional Autó noma de Nicaragua', Leon (Nicaragua). Both the Cuban and the Nicaraguan populations were recruited following the same protocol previously used in Spain, 23 with a similar research team, in order to avoid potential selection bias because of the influence of CYP2D6 genotype on psychological features. 24 A routine clinical examination was carried out and the medical history was taken before the study. Volunteers with a previous history of adverse drug effects and those with any drug intake in the 2 weeks before the study were excluded. The subjects were informed about the aims of the study and gave their written Informed Consent before their participation. The study was conducted according to the Helsinki Declaration, and it was approved by the Local Ethics Committees of the institutions involved. Although some CYP2D6 allele frequencies have already been published for the Nicaraguan population, 25 a new genotyping analysis including CYP2D6*6, CYP2D6*17 and CYP2D6*4xN has been carried out in order to improve the accuracy of the geno-pheno relationship analysis. Some data about Cubans' debrisoquine hydroxylation phenotype have already been published. 26, 27 Phenotyping procedure The subjects took a single oral dose of 10 mg of debrisoquine sulfate (Declinax; Hoffman-La Roche, Switzerland) and after an overnight fast all urine was collected over 8 h. The samples were kept frozen at -201C and transported from Havana (Cuba) and Leon (Nicaragua) to Badajoz (Spain) where analyses were carried out. The analytical determination was performed by high-performance liquid chromatography-ultraviolet according to our previously reported methodology. 23, 28 Debrisoquine hydroxylation phenotype was assigned by the debrisoquine metabolic ratio (MR), defined as the ratio of the molar concentration of the parent drug and that of 4-hydroxydebrisoquine in the 0-8 h urine output. The antimode for each histogram was calculated according to the Probit plot. Individuals with an MR 412.6 (log10 MRX1.1) were considered as PMs, whereas the rest were classified as EMs. Among EMs, a cut-off point of MRp0.1 was used to classify the UMs. 17, 15, 29 Genotyping procedure Blood samples (10 ml) were collected in EDTA tubes, and DNA was extracted using the QIAamp DNA blood kit (QIAGEN, Hilden, Germany). The CYP2D6 genotype was analyzed by PCR and PCR-restriction fragment length polymorphism for the CYP2D6 *3, *4, *5, *6, *10, *17, and multiplicated alleles. 30 The relationship between CYP2D6 genotype and phenotype was evaluated assigning a value relative to each variant CYP2D6 allele based on the 'activity score' system. 22 The value assigned to the reference allele CYP2D6 wt (*1 or *2) was 1, whereas to CYP2D6*3, *4, *4xN, *5, *6 variants were assigned the value of 0, to CYP2D6*10 and *17 alleles were assigned 0.5, and to multiplications of CYP2D6wt (*1xN or *2xN) allele with 2.
Statistical analysis
Mean MR values of EMs in the three different populations were compared by using unpaired t-test. The correlations between 'activity scores' and MR where analyzed by Spearman's rank correlation coefficient. Mean MRs among different 'activity scores' were compared with non-parametric Kruskal-Wallis test with Dunn's multiple comparison test. The differences in CYP2D6 allele frequencies were compared by using the w 2 -test and/or Fisher's exact test. P-values o0.05 were regarded as statistically significant. Statistical analysis was performed using STATISTICA 4.3 (StatSoft, Tulsa, OK, USA) and GraphPad Prism 3.02 (GraphPad Software , San Diego, CA, USA) programs.
Results
Debrisoquine hydroxylation phenotype
The MR histograms revealed a bimodal distribution of CYP2D6 activity in the three populations (Figure 1 ). The frequency of individuals classified as PMs was 5.3, 3.9 and 6.0% in WCs, CMs and NMs, respectively. The frequency of UMs was 5.3% for WC, 2.3% for CM and 0% for NM. Mean (±s.d.) MR values among EMs (Figure 1 ) was higher among NMs (1.5 ± 1.6; n ¼ 118; Po0.001) than among CWs (0.7±1.0; n ¼ 124; Po0.001) and CMs (1.0±1.3; n ¼ 124; Po0.001). No significant association was found with gender, tobacco smoking or alcohol intake habits in Nicaraguans or Cubans.
CYP2D6 genetic polymorphism
The frequencies of the CYP2D6 genotypes in all the studied populations (Table 2 ) corresponded with those predicted by the Hardy-Weinberg law. The percentage of individuals with zero CYP2D6 active genes was 2.3% in WCs, 2.4% in CMs and 4.1% in NMs (Table 3 ).
The percentage of CYP2D6*17 alleles among CMs (10.2%) was higher than among WC (2.7%; Po0.005) individuals and NMs, in whom it was not detected. The CYP2D6*10 allele was higher in NMs (3.1%) than in WCs (0.4%; Po0.05) and CMs (0.8%; Po0.05). With regard to duplications/ multiplications (CYP2D6*1xN or *2xN alleles), although in NMs were observed to be lower (2%) than in WCs (3.8%), and CMs (4.7%), there were no statistical differences.
CYP2D6 genetic polymorphism and debrisoquine hydroxylation phenotype A total of 123 WCs, 120 CMs and 93 NMs were phenotyped and genotyped to CYP2D6. All individuals CYP2D6*4/*4 and CYP2D6*4/*5 were also phenotypically PMs (n ¼ 10). The rest of phenotypically PMs (n ¼ 5) were individuals with CYP2D6 wt/*10 (n ¼ 2), wt/*4, *5/*10 or wt/*4xN (n ¼ 3) genotypes. Among UMs, 40% carried multiplications of CYP2D6 active alleles (42 active genes). In addition, these individuals with more than two active genes versus those who carried one or two copies presented a lower MR (Po0.05).
MR correlated with the 'activity score' of CYP2D6 genotypes among all 336 healthy volunteers (Po0.05; r ¼ À0.55; Figure 2a ). Moreover, MR varied across subjects with different CYP2D6 'activity score' (Po0.0001). Figure 2b shows the relationship between 'activity score' and MR in the three populations. Overall, NMs seemed to show a higher MR than WCs or CMs (Figure 2b ). In particular, MR mean was higher in NMs than in WCs and CMs for the groups classified as 1 (Po0.05) or 2 (Po0.01) 'activity score'.
Mean (±s.d.) MR among subjects with CYP2D6wt/*17 (n ¼ 24; 1.42 ± 2.05) and *4/*17 (n ¼ 6; 4.10 ± 2.48) genotypes was higher (Po0.001) than among those with CYP2D6wt/wt genotype (n ¼ 124; 0.59±0.77).
Discussion
This study demonstrates the existence of CYP2D6 hydroxylation polymorphism using debrisoquine as a test substrate in Latino populations of WC, CM and NM (PMs were 5.3, 3.9, 6% and UMs were 5.3, 2.3, 0%, respectively). MR among EMs was higher in NMs than in CMs and WCs. MR was related to CYP2D6 'activity score'. MR was higher among NMs than WCs and CMs for groups classified as 1 or 2 'activity score'. In addition, MR was higher among subjects carrying CYP2D6*17 than in CYP2D6 wt/wt. Allelic distributions of CYP2D6 genes differed among the Latino groups studied here indicating ethnic variety within this large population (CYP2D6*10 and CYP2D6*17 were higher in NMs and CMs, respectively). Thus, the variability in CYP2D6 phenotypes found may be related to differences in allele frequency among groups.
Debrisoquine hydroxylation phenotypes PM phenotype frequencies were all similar to that found in White Spaniards (4.9%), 17 and higher than those reported in Oriental [31] [32] [33] and African populations. 3 Studies in Ngawbé Guaymí Amerindians from Central America have reported a similar frequency of PMs (around 5%). However, evidence about the absence of PMs in Cuna Amerindians also exists (Table 1 ). 
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Among phenotypically EMs, MR was higher in NMs than WCs or CMs, which may be probably because of the differences in the presence of defective or null alleles (CYP2D6*10 was highest in NMs), as well as to other environmental factors, such as food, lifestyle and so on.
UM subjects were not found in NMs, whereas the frequency in WCs was similar to that found in White Spaniards (5.2%).
17
CYP2D6 genetic polymorphism: frequency of defective (null or deficient activity) alleles The frequency of CYP2D6*4 in WCs was similar to other American Caucasian populations. [34] [35] [36] In CMs, it was higher (14.6%) than in Black populations. 3, 34, 35, [37] [38] [39] [40] [41] In NMs (14.2%) was similar to some Amerindians 8 and Spaniards (Table 1) , and higher than in Mapuches and Tepehuanos. 9, 14 The CYP2D6*10 defective allele occurred up to three times more frequently in NMs than in WCs and CMs (Table 1) . CYP2D6*17 allele with diminished function occurred up to four times more frequently in CMs than in WCs, whereas it was not found in the NM population. CYP2D6*17 frequency in CMs was similar to those observed in black populations, 34, 35, 38, 39, [41] [42] [43] and higher than those reported in Central or South Americans, 8, 6 Caucasians from America, 35, 36 and other European populations. 34, 42 The frequency of CYP2D6 duplication/multiplication in WCs and CMs (4-5%) was similar to the one found in Spaniards 17 ( Tables 1 and 3) .
Effect of CYP2D6 genetic polymorphism on debrisoquine hydroxylation All individuals homozygous for the non-functional CYP2D6 alleles were also found to be phenotypically PMs. However, only 67% of PMs carried zero active genes. Therefore, reduced activity alleles need to be studied, similar to the CYP2D6*29 reported in Africans from Tanzania, 44 which is acknowledged as a limitation of this study. Moreover, only 23.5% of subjects with CYP2D6 gene multiplications were phenotypically UMs, and only 40% of individuals with UM phenotype showed duplications. This result is consistent with other previously observed in Caucasian populations. 45 It is also in agreement with previous findings showing that genotyping for duplicated/multiplicated CYP2D6 active alleles only explains a fraction (10-30%) of the ultrarapid phenotype observed in Caucasian populations. 29, 46, 47 The results also show that CMs present a higher MR than WCs, which is consistent with results from Black-African descendant studies. 35, 36 This could be explained by the higher frequency of CYP2D6*17 defective alleles in CMs than in WCs, which is also shown by present results about lower CYP2D6 activity in individuals carrying CYP2D6*17 than in homozygous wild-type subjects (Figure 3 ). On the other hand, the MR of NMs was higher than the MR of Cubans, which may be related to the presence of CYP2D6*10 ( Figure 2b) . Moreover, differences between populations are observed across activity score groups. Thus, these facts are probably because of the environmental and genetic factors that may influence variability in CYP2D6 activity.
This study has shown a relationship between CYP2D6 genotyping and debrisoquine phenotyping using 'activity score' 22 and variability across Latin groups. This is of clinical relevance considering CYP2D6 involvement in the metabolism of a large number of commonly prescribed drugs. 1 Thus, CYP2D6 genotyping may be a useful tool to predict drug related side effects, interactions or therapeutic failure 17 in these populations. Although population pharmacogenetics could be of some use in terms of public health care policies, several studies have shown that genetic differences between individuals are higher than between ethnic groups or races. 1, 2, 17 Thus, in a heterogeneous population, such as Latinos, it would be more adequate to consider the individual than an ethnic-based approach for personalized medicine. 48 In the light of these findings, we could hypothesize that drugs metabolized by CYP2D6 may show different profile of efficacy/adverse effects in NM, CM and WC populations. Therefore, further research on different ethnic groups in America is warranted.
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